Citadel Advisors
DMAA icon

Citadel Advisors’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Citadel Advisors’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,476
Closed -$110K – 15235
2026
Q1 		$110K Buy
+10,476
New +$109K ﹤0.01% 11922

Other funds holding DMAA

Karpus Investment Management
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
Mizuho Securities USA
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
First Trust Capital Management
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
Heights Capital Management
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Westchester Capital Management (New York)
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
Aristeia Capital
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Citadel Advisors's DMAA Position: Q2 2026 in Review

Citadel Advisors sold out of Drugs Made In America Acquisition Corp (DMAA) in Q2 2026, closing a stake of 10,476 shares — an estimated $110K sold.

Citadel Advisors first reported a position in DMAA in Q1 2026 and held it in 1 quarter. The position peaked at $110K in Q1 2026. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.

  • Citadel Advisors reported no remaining Drugs Made In America Acquisition Corp position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 10,476 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $110K.
  • Citadel Advisors first reported a position in Drugs Made In America Acquisition Corp in Q1 2026 and held it in 1 quarter.
  • Citadel Advisors's Drugs Made In America Acquisition Corp position peaked at $110K in Q1 2026.
  • 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.